Saturday, March 25, 2023
As an organization accredited by the ACCME, Medscape requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as "financial relationships in any amount, occurring within the past 12 months," that could create a conflict of interest.
Medscape encourages Authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.
Associate Professor, Residency Director, Department of Family Medicine, University of California, Irvine
This article is intended for primary care physicians, urologists, geriatricians, and other specialists who care for older men.
The goal of this activity is to provide the latest medical news to physicians and other healthcare professionals in order to enhance patient care.
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as "financial relationships in any amount, occurring within the past 12 months," that could create a conflict of interest.
Medscape encourages Authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.
Associate Professor, Residency Director, Department of Family Medicine, University of California, Irvine
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape designates this educational activity for 0.25 category 1 credit(s) toward the AMA Physician's Recognition Award. Each physician should claim only those credits that reflect the time he/she actually spent in the activity.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print
out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.
*The credit that you receive is based on your user profile.
CME Released: 4/14/2004; Reviewed and Renewed: 4/14/2005
Valid for credit through: 4/14/2006
processing....
April 14, 2004 — Carnitine is more active than testosterone for improving symptoms of male aging such as sexual dysfunction, depressed mood, and fatigue, according to the results of a randomized study published in the April issue of Urology.
"Testosterone increases the tissue carnitine concentration," write G. Cavallini, from the Società Italiana di Studi di Medicina della Riproduzione in Bologna, Italy. "Propionyl-L-carnitine and acetyl-L-carnitine proved active for diseases typical of aging."
In this trial, 120 patients were randomized to receive testosterone undecanoate 160 mg/day, propionyl-L-carnitine 2 g/day plus acetyl-L-carnitine 2 g/day, or placebo for six months. Mean age was 66 years (range, 60-74 years).
Compared with baseline, testosterone and carnitines significantly improved the peak systolic velocity, end-diastolic velocity, and resistive index of cavernosal penile arteries, as well as nocturnal penile tumescence (NPT), International Index of Erectile Function score, Depression Melancholia Scale score, and fatigue scale score.
Compared with testosterone, carnitines were significantly more active in improving NPT and International Index of Erectile Function score. Testosterone, but not carnitines, significantly increased the prostate volume and free and total testosterone levels and significantly lowered serum luteinizing hormone. Prostate-specific antigen (PSA) and prolactin did not change significantly in any group.
No symptoms or physiological markers improved in the placebo group. Adverse effects were negligible in all groups.
Carnitines and testosterone were effective for as long as they were administered, with reversal to baseline values when treatment was stopped. Six months after testosterone suspension, prostate volume remained significantly greater than baseline.
"Testosterone and, especially, carnitines proved to be active drugs for the therapy of symptoms associated with male aging," the authors write. "At least one side effect of testosterone administration (i.e. prostate enlargement) will be avoided by carnitine administration."
Two of the authors are patent inventors for use of carnitines in treating symptoms of male aging.
Urology. 2004;63:641-646
